FK506-Induced Fulminant Leukoencephalopathy After Single-Lung Transplantation
Section snippets
Comment
FK506 is being used increasingly in organ transplantation to prevent and treat rejection. Although neurotoxicity of this agent has been described [5] after liver and kidney transplantation, reports after lung transplantation are extremely rare.
The incidence of FK506-induced neurotoxicity, which may be early (<2 weeks) or late (>2 months) [3], varies from 5% to 30% in the literature 3., 4., 5.. The spectrum of neurologic complications may range from mild (tremors, paresthesias, and mild organic
References (10)
- et al.
Clinical trial of tacrolimus versus cyclosporine in lung transplantation
Ann Thorac Surg
(1995) - et al.
Use of FK 506 in pediatric patients
Transplant Proc
(1991) - et al.
Neurotoxicity after orthotopic liver transplantation
Transplantation
(1994) - et al.
Adverse effects associated with the use of FK506
Transplant Proc
(1991) - et al.
Neurologic complications of FK 506
Transplant Proc
(1991)
There are more references available in the full text version of this article.
Cited by (0)
Copyright © 1997 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.